within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BC59_TrifluridineCombinations;

model TrifluridineCombinations
  extends Pharmacolibrary.Drugs.ATC.L.L01BC59;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01BC59</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Trifluridine in combination (notably with tipiracil as L01BC59) is an antineoplastic agent used in the treatment of metastatic colorectal cancer. Trifluridine is a nucleoside analog which inhibits thymidylate synthase and gets incorporated into DNA, resulting in cytotoxicity. The combination with tipiracil inhibits trifluridine degradation, increasing its bioavailability. This combination has received regulatory approval for use in patients who have been previously treated with standard chemotherapeutic regimens.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult cancer patients (including both sexes, median age approximately 63, not kidney/liver impaired), under multiple-dose conditions at therapeutic doses.</p><h4>References</h4><ol><li><p>Chan, BM, et al., &amp; Lenz, HJ (2019). The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective. <i>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</i> 76(6) 339–348. DOI:<a href=&quot;https://doi.org/10.1093/ajhp/zxy006&quot;>10.1093/ajhp/zxy006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31361848/&quot;>https://pubmed.ncbi.nlm.nih.gov/31361848</a></p></li><li><p>Cleary, JM, et al., &amp; Sun, W (2017). A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone. <i>Investigational new drugs</i> 35(2) 189–197. DOI:<a href=&quot;https://doi.org/10.1007/s10637-016-0409-9&quot;>10.1007/s10637-016-0409-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28111727/&quot;>https://pubmed.ncbi.nlm.nih.gov/28111727</a></p></li><li><p>Becerra, CR, et al., &amp; Von Hoff, D (2017). A Phase 1, Open-Label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 (Trifluridine/Tipiracil) Tablets Relative to an Oral Solution Containing Equivalent Amounts of Trifluridine and Tipiracil. <i>Journal of clinical pharmacology</i> 57(6) 751–759. DOI:<a href=&quot;https://doi.org/10.1002/jcph.856&quot;>10.1002/jcph.856</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28070894/&quot;>https://pubmed.ncbi.nlm.nih.gov/28070894</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end TrifluridineCombinations;
